ARTICLE | Company News
Prosensa, GlaxoSmithKline deal
October 19, 2009 7:00 AM UTC
Prosensa granted GlaxoSmithKline exclusive, worldwide rights to develop and commercialize PRO051. The antisense oligoribonucleotide that induces exon 51 skipping on the dystrophin gene is expected to start Phase III testing early next year to treat Duchenne muscular dystrophy (DMD). GSK also has an exclusive option to license three more RNA-based compounds targeting additional DMD exons, including PRO044, which is expected to start a Phase I/II trial by year end. GSK's option for PRO044, which induces skipping of exon 44, will be triggered by completion of the Phase I/II study. The two other compounds were not disclosed. ...